Ritlecitinib (tosylate)
Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M) . Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) [1][2][3].
Product Specifications
CAS Number
2192215-81-7
Product Name Alternative
PF-06651600 (tosylate)
UNSPSC
12352005
Target
Interleukin Related; JAK; STAT
Type
Reference compound
Related Pathways
Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ritlecitinib-tosylate.html
Purity
99.77
Solubility
DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC(C=C1)=CC=C1S(O)(=O)=O.C=CC(N2[C@@H](C)CC[C@@H](NC3=C4C(NC=C4)=NC=N3)C2)=O
Molecular Formula
C22H27N5O4S
Molecular Weight
457.55
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
IL-15; IL-2; IL-4; IL-7; JAK3; STAT3; STAT5; STAT6
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45 / LCA (2B11 + PD7/26), CF647 conjugate, 0.1mg/mL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF640R conjugate, 0.1mg/mL
Fibronectin (TV-1), CF405S conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF488A conjugate, 0.1mg/mL
